Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

Autor: Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz, Schneider, Christof, Gribben, John G., Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J.

Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform molecular c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7f8c318f99811f6760041817aacf110

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.

Autor: Bloehdorn J; Department of Internal Medicine III, University of Ulm, Ulm, Germany. johannes.bloehdorn@gmail.com., Braun A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Taylor-Weiner A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Jebaraj BMC; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Robrecht S; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Pan H; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA., Giza A; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Akylzhanova G; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Holzmann K; Genomics Core Facility, Ulm University, Ulm, Germany., Scheffold A; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Johnston HE; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Yeh RF; Biostatistics, Genentech Inc., South San Francisco, CA, USA., Klymenko T; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Tausch E; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Eichhorst B; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Bullinger L; Medical Clinic for Hematology, Oncology and Tumor Biology, Charité University Hospital, Berlin, Germany., Fischer K; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Weisser M; Roche Pharma Research and Early Development, Penzberg, Germany., Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland., Schneider C; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Gribben J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Dahal LN; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.; Department of Pharmacology and Therapeutics, Faculty of Life and Health Sciences, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Carter MJ; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Elemento O; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Landau DA; Cancer Genomics and Evolutionary Dynamics, Weill Cornell Medicine, New York, NY, USA.; New York Genome Center, New York, NY, USA., Neuberg DS; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Cragg MS; Centre for Cancer Immunology, Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Hallek M; Department I for Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany., Wu CJ; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Mertens D; Department of Internal Medicine III, University of Ulm, Ulm, Germany. d.mertens@dkfz-heidelberg.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. d.mertens@dkfz-heidelberg.de.

Publikováno v: Nature communications [Nat Commun] 2021 Sep 13; Vol. 12 (1), pp. 5395. Date of Electronic Publication: 2021 Sep 13.